Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

Sponsor
Federico II University
Study ID
NCT07375225
Status
Recruiting
Apply to this trial

Conditions

  • Hypercholesterolaemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.

Key Dates

Start date
Dec 1, 2024
Status verified
Jan 2026
Primary completion
Dec 1, 2026
Completion
Dec 1, 2027

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Subjects with hyperlipidaemia under Alirocumab 300 mg treatment.
    Subjects with hyperlipidaemia

Primary Outcome Measure

Description of adherence of treatment with alirocumab 300mg in a real-life Italian population. [ Time Frame: 6-12-24-36 months ]

Central Contacts

Related Studies